Guangzhou Burning Rock Dx Co., Ltd.
18
5
6
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
Role: collaborator
A Proof of Concept Study of Pan-cancer Early Detection by Liquid Biopsy
Role: collaborator
MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
Role: collaborator
Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer Recurrence
Role: collaborator
PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II
Role: collaborator
Primary Liver Cancer Early Detection
Role: collaborator
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
Role: collaborator
The Unintrusive Detection of EaRly-stage Cancers
Role: collaborator
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
Role: collaborator
Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
Role: collaborator
AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial Tumors
Role: collaborator
Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention
Role: collaborator
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
Role: lead
Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies
Role: collaborator
Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT
Role: collaborator
Pan-canceR Early DetectIon projeCT (PREDICT)
Role: collaborator
Pan-canceR Early DetectIon projeCT
Role: lead
Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Role: collaborator
All 18 trials loaded